Long survival of a patient from Matanzas with lung cancer and brain metastasis. Case report
Keywords:
Monoclonal antibodies, Non-small cell lung carcinoma, Neoplasia Metastasis, SurvivalAbstract
Lung cancer is the leading cause of death from malignant tumors, with non-small cell cancer being the most common. This ischaracterized by a tendency to metatize important organs such as the central nervous system, for which an average survival
of three to six months is estimated after being treated with radiation. We present the case of a 55-year-old patient, non-smoker, who was studied in the Oncology service, where studies were carried out, observing a nodular image in the lower lobe of the right lung; sample was taken that she reported squamous cell carcinoma, stage T2aN0M0 Stage Ib. Several treatment schemes
were implemented, including surgical intervention. In November 2018 she passes away. She is a patient with a diagnosis of
squamous cell carcinoma of the lung with brain and bone metastases who achieved an overall survival of six years, exceeding the average established to date.
References
American Cancer Society [Internet]. Washington: American Cancer Society; 2019 [actualizado 2021; citado 26/04/2021]. Disponible en: http://www.cancer.org/cancer/acs-medical-content-and-staff.html
Ministerio de Salud Pública. Dirección de Registros Médicos y Estadísticas de Salud. Anuario Estadístico de Salud 2019. [Internet] La Habana; 2020[citado 21/04/2021]. Disponible en: http://files.sld.cu/bvscuba/files/2020/05/Anua-rio-Electr%C3%B3nico-Espa%-C3%B1ol-2019-ed-2020.pdf
Camacho Sosa K, Santiesteban Álvarez E, Herrera Suárez A, Carreño Rolando IE. Ensayos clínicos en pacientes con cáncer de pulmón en Matanzas. Rev. med. electronica [Internet]. 2019 [citado 21/04/2021] 41(5):[aprox. 0p.] Disponible en: http://revmedicaelectronica.sld.cu/index.php/rme/article/view/3383
Reck M, Popat S, Reinmuth N, De Ruysscher D, Kerr KM, Peters S. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology [Internet]. 2014 [citado 26/04/2021]; 25(3):27-39. Disponible en: https://doi.org/10.1093/annonc/mdu199.
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin [Internet]. 2010 [citado 27/04/2021]; 60(5):277-300. Disponible en: http://onlinelibrary.wiley.com/doi/10.3322/caac.20073/
Pallis AG, Syrigos K. Targeted(and chemotherapeutic) agents as maintenance treatment in patients with metastatic non-small-cell lung cancer: Current status and future challenges. Cancer Treat Reviews [Internet]. 2012 [citado 25/04/2021]; 38(7):861-867. Disponible en: https://pubmed.ncbi.nlm.nih.gov/22217701/.
American Cancer Society [Internet]. Washigton: American Cancer Society; 2019 [actualizado 2021; citado 26/04/2021]. Tratamiento del cáncer de pulmón no microcítico. Disponible en: https://www.cancer.org/content/dam/CRC/PDF/Public/9439.00.pdf
Barker AJ, Gibson KH, Grundy W, Godfrey AA, Barlow JJ, HealyMP, et al. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett [Internet]. 2001 [citado 21/04/2021]; 11(14):191-4. Disponible en: https://pubmed.ncbi.nlm.nih.gov/11459659/
Hua/qing W, Yangang R, Zheng/zi Q, Kai F, Hui/lai Z, Wei Li, et al. Nimotuzumab combined with gemcitabine and cisplatin as second/line chemotherapy for advancednon/small/cell lung cancer. Thoracic Cancer [Internet]. 2012 [citado 27/04/2021]; 3(1):72-78. Disponible en: https://pubmed.ncbi.nlm.nih.gov/11459659/
CECMED. [Internet] La Habana: CECMED; 2019 [citado 28/04/2021]. Resumen de las características del producto CIMAHER (Nimotuzumab). Disponible en https://www.cecmed.cu/sites/default/files/adjuntos/rcp/biologicos/rcp_cimaher.pdf
González-Palomo A, Carr-Pérez A, León-Monzón K, Blanco R, López-Medinilla A. El receptor del factor de crecimiento epidérmico y el N-glicolil GM3 y su contribución a la progresión tumoral. Bases para una inmunoterapia combinada. Anales de la Academia de Ciencias de Cuba [Internet]. 2019 [21/04/2021]; 9(3): [aprox. 716 p.]. Disponible en: http://www.revistaccuba.sld.cu/index.php/revacc/article/view/716
Hernández Casola T, Pérez Morales Y, Trujillo Tirado T. Elevada supervivencia en paciente con cáncer de pulmón avanzado tratada con Vaxira®. MediCiego [Internet]. 2020 [citado 21/04/2021]; 26(1):[aprox. 0 p.]. Disponible en: http://www.revmediciego.sld.cu/index.php/mediciego/article/view/1125
Ministerio de Salud Pública. Dirección de Registros Médicos y Estadísticas de Salud. Anuario Estadístico de Salud 2019. [Internet] La Habana; 2020[citado 21/04/2021]. Disponible en: http://files.sld.cu/bvscuba/files/2020/05/Anua-rio-Electr%C3%B3nico-Espa%-C3%B1ol-2019-ed-2020.pdf
Camacho Sosa K, Santiesteban Álvarez E, Herrera Suárez A, Carreño Rolando IE. Ensayos clínicos en pacientes con cáncer de pulmón en Matanzas. Rev. med. electronica [Internet]. 2019 [citado 21/04/2021] 41(5):[aprox. 0p.] Disponible en: http://revmedicaelectronica.sld.cu/index.php/rme/article/view/3383
Reck M, Popat S, Reinmuth N, De Ruysscher D, Kerr KM, Peters S. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology [Internet]. 2014 [citado 26/04/2021]; 25(3):27-39. Disponible en: https://doi.org/10.1093/annonc/mdu199.
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin [Internet]. 2010 [citado 27/04/2021]; 60(5):277-300. Disponible en: http://onlinelibrary.wiley.com/doi/10.3322/caac.20073/
Pallis AG, Syrigos K. Targeted(and chemotherapeutic) agents as maintenance treatment in patients with metastatic non-small-cell lung cancer: Current status and future challenges. Cancer Treat Reviews [Internet]. 2012 [citado 25/04/2021]; 38(7):861-867. Disponible en: https://pubmed.ncbi.nlm.nih.gov/22217701/.
American Cancer Society [Internet]. Washigton: American Cancer Society; 2019 [actualizado 2021; citado 26/04/2021]. Tratamiento del cáncer de pulmón no microcítico. Disponible en: https://www.cancer.org/content/dam/CRC/PDF/Public/9439.00.pdf
Barker AJ, Gibson KH, Grundy W, Godfrey AA, Barlow JJ, HealyMP, et al. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett [Internet]. 2001 [citado 21/04/2021]; 11(14):191-4. Disponible en: https://pubmed.ncbi.nlm.nih.gov/11459659/
Hua/qing W, Yangang R, Zheng/zi Q, Kai F, Hui/lai Z, Wei Li, et al. Nimotuzumab combined with gemcitabine and cisplatin as second/line chemotherapy for advancednon/small/cell lung cancer. Thoracic Cancer [Internet]. 2012 [citado 27/04/2021]; 3(1):72-78. Disponible en: https://pubmed.ncbi.nlm.nih.gov/11459659/
CECMED. [Internet] La Habana: CECMED; 2019 [citado 28/04/2021]. Resumen de las características del producto CIMAHER (Nimotuzumab). Disponible en https://www.cecmed.cu/sites/default/files/adjuntos/rcp/biologicos/rcp_cimaher.pdf
González-Palomo A, Carr-Pérez A, León-Monzón K, Blanco R, López-Medinilla A. El receptor del factor de crecimiento epidérmico y el N-glicolil GM3 y su contribución a la progresión tumoral. Bases para una inmunoterapia combinada. Anales de la Academia de Ciencias de Cuba [Internet]. 2019 [21/04/2021]; 9(3): [aprox. 716 p.]. Disponible en: http://www.revistaccuba.sld.cu/index.php/revacc/article/view/716
Hernández Casola T, Pérez Morales Y, Trujillo Tirado T. Elevada supervivencia en paciente con cáncer de pulmón avanzado tratada con Vaxira®. MediCiego [Internet]. 2020 [citado 21/04/2021]; 26(1):[aprox. 0 p.]. Disponible en: http://www.revmediciego.sld.cu/index.php/mediciego/article/view/1125
Downloads
Published
2022-01-05
How to Cite
1.
Sánchez-Lazo Y, Camacho-Sosa K, Martí-Coruña C. Long survival of a patient from Matanzas with lung cancer and brain metastasis. Case report. Rev 16 de abril [Internet]. 2022 Jan. 5 [cited 2024 Dec. 18];61(283):e1108. Available from: https://rev16deabril.sld.cu/index.php/16_04/article/view/1108
Issue
Section
Case Report
License
Those authors who have publications with this journal, accept the following terms:
The authors will retain their copyright and guarantee the journal the right of first publication of your work, which will be under a Creative license Commons Attribution-NonCommercial-ShareAlike 4.0 International . (CC BY-NC-SA 4.0).
The authors may adopt other non-exclusive license agreements for the distribution of the published version of the work (eg:deposit it in an institutional telemat
